Coagulation Disorders in Patients With Cirrhosis

Publication Date: September 24, 2021

Key Points

Key Points

  • Significant alterations in laboratory parameters — such as platelet count (PLT) and prothrombin time/international normalized ratio (PT/INR) — routinely accompany cirrhosis.
    • However, the risks of both bleeding and thrombosis are not accurately quantitated by standard testing in this population.
  • The best strategies to identify patients at risk for bleeding or thrombosis, to provide appropriate prophylaxis in patients at risk for clinically significant bleeding, to screen for and treat portal vein thrombosis, and to prevent clinically significant thromboembolic events are currently unknown.

Diagnosis

...iagnosis

...sting Strategy

...esting (VET)In patients with stable cirrho...

...patients with stable cirrhosis (with know...


...Thrombosis (PVT) Screening...

...s with cirrhosis, the AGA suggests agains...


Treatment

...atment...

...reprocedure Prophy...

...LT and/or Fresh Frozen Plasma (FFP)In pat...

...in receptor agonist (TPO-Ras)In patients wi...


...s Thromboembolism (VTE) Prophylaxis With Anticoagu...

...talized patients with cirrhosis and who otherwis...


...or Subacute Non-tumoral Portal Vein Thro...

...with cirrhosis and acute or subacut...


Atrial Fibrillatio...

...atients with cirrhosis and atrial fibrillatio...


...ocedure Risk StratificationHaving t...